Decentralized Trials Curebase has a strong focus on democratizing clinical trials with decentralized, virtual, and hybrid site capabilities. This positions them well to upsell to sponsors seeking broader patient access, faster recruitment, and reduced site burden through a unified AI-native eClinical platform.

Unified eClinical Platform Their single unified system spanning recruitment, eConsent, eCOA/ePRO, EDC, engagement, and site software suggests cross-sell opportunities to sponsors and sites already using disparate tools. Emphasize value of data pristine quality and end-to-end workflow simplification.

Sponsor to Site Value Curebase emphasizes delivering pristine data to sponsors and modern tech to sites, creating a compelling case for partnerships with mid-market sponsors seeking efficiency gains and with sites looking for cost-free advanced tools, enabling channel partner collaborations.

Strategic Partnerships Recent and ongoing partnerships ( Walgreens collaboration, Redenlab integration, BEKhealth alliance) indicate a growth strategy through ecosystem building. Sales plays can target similar CROs, biopharma sponsors, and platform integrators seeking enhanced reach and compliance capabilities.

Financial Readiness With mid-range revenue and Series B funding, Curebase is positioned to scale. Proposals can frame ROI on faster trial completion, improved data quality, and access to AI-driven automation, aligning with investor and procurement priorities in clinical research programs.